Q-omics provides the consensus-scored RPL12P9 profile across patient tissues and cancer cell-line models. RPL12P9 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPL12P9 is differentially expressed in 6, with the highest sampling consensus in CHOL. Additionally, RPL12P9 RNA expression shows 11,457 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CHOL, and DLBC as cancer lineages where RPL12P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P9 survival associations across molecular data types. RPL12P9 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P9 RNA expression–survival associations across cancer types. High RPL12P9 expression shows unfavorable associations in CHOL, MESO, LGG, THCA and PCPG, but favorable associations in STAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify CHOL as the clearest survival context for RPL12P9 RNA expression.
This table summarizes RPL12P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P9 shows lower tumor expression in KICH and LUSC and higher tumor expression in CHOL, BLCA, LIHC and COAD. The CHOL box plot shows higher RPL12P9 RNA expression in tumor versus normal tissue (log2 FC = +0.277, t-test p = .012).
This table shows molecular features associated with RPL12P9 in patient tissues and cancer cell lines. In patient samples, RPL12P9 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
